(7S,9S)-7-(4-amino-5-hydroxy-6-methyloxan-2-yl)oxy-6,9,11-trihydroxy-4-methoxy-9-(2-methoxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 蒽环类药物
• 英文名称: (7S,9S)-7-(4-amino-5-hydroxy-6-methyloxan-2-yl)oxy-6,9,11-trihydroxy-4-methoxy-9-(2-methoxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione
• 化学式: C₂₈H₃₁NO₁₁
• 分子量: 557.5
• InChiKey: KHXUHAHJGPAIOL-PHKCKUDBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  40
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  195
• 氢给体数：
  5
• 氢受体数：
  12

文献信息

• Doxorubicin Immunoassay
  申请人：Salamone Salvatore J.

  公开号：US20090215078A1

  公开（公告）日：2009-08-27

  Novel conjugates of doxorubicin and novel doxorubicin immunogens derived from the 13 and 14 positions of doxorubicin and antibodies generated by these doxorubicin linked immunogens all of which are useful in immunoassays for the quantification and monitoring of doxorubicin in biological fluids.
• METHODS OF TREATING CANCER USING COMPOUNDS CONTAINING A VASCULAR DISRUPTING AGENT
  申请人：Ellipses Pharma Limited

  公开号：US20200316212A1

  公开（公告）日：2020-10-08

  The present invention relates to prodrugs of vascular disrupting agents comprising a vascular disrupting agent (VDA) associated with a MMP proteolytic cleavage site and to the use of such prodrugs in the targeted treatment of cancer.